omniture
logo
Search
迪哲医药
Media Room

Latest News

rss

Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO

PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data f...

2022-09-05 22:39 2487

Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022

Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion ...

2022-05-27 18:00 1696

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing ph...

2022-05-13 19:09 2636

FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion

SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), tod...

2022-01-27 21:15 3567
12